The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial
| Autor: | Shadi Eghbal-Fard, Mehrzad Hajialilo, Hanieh Heydarlou, Badrossadat Rahnama, Hossein Samadi Kafil, Arezou Ghassembaglou, Mehdi Yousefi, Mahnaz Ghaebi, Amin Kamrani, Reza Rikhtegar, Sanam Dolati, Leili Aghebati-Maleki, Majid Ahmadi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Curcumin Inflammation Placebo T-Lymphocytes Regulatory Biochemistry Flow cytometry Young Adult 03 medical and health sciences 0302 clinical medicine Double-Blind Method Transforming Growth Factor beta microRNA medicine Humans Spondylitis Ankylosing Secretion Molecular Biology Ankylosing spondylitis medicine.diagnostic_test Interleukin-6 business.industry FOXP3 Forkhead Transcription Factors Cell Biology Middle Aged medicine.disease Interleukin-10 Clinical trial MicroRNAs 030104 developmental biology 030220 oncology & carcinogenesis Immunology Leukocytes Mononuclear Nanoparticles Female medicine.symptom business |
| Zdroj: | Journal of Cellular Biochemistry. 121:103-110 |
| ISSN: | 1097-4644 0730-2312 |
| Popis: | AIM Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with increased bone mass in the main sites of inflammation. Regulatory T (Treg) cells have been reported to involve in pathology of AS. This study designed at investigating the effects of nanocurcumin on Treg cell responses in peripheral blood (PB) of AS patients. METHODS Test group including 12 AS patients received nanocurcumin daily for 4 months and control group including 12 patients received placebo. The frequency of Treg was measured by flow cytometry. The expression levels of FoxP3 and several associated microRNAs (miRNAs; miR-27, miR-17, and miR-146a) and cytokines including Interleukin-10 (IL-10), TGF-β, and IL-6 were assessed by real-time polymerase chain reaction. Furthermore, enzyme-linked immunosorbent assay was done to determine the secretion levels of cytokines. RESULTS After treatment with nanocurcumin the frequency of Treg cells in AS patients increased significantly. The RT-PCR data indicated that the expression of miR-17 and miR-27 were significantly decreased following nanocurcumin treatment while miR-146a and FoxP3 were significantly increased. Moreover, nanocurcumin-treated group had high levels of IL-10 and TGF-β and low levels of IL-6 production than control group. CONCLUSION The findings suggested that dysregulation of Treg cells in PB influences the AS development and nanocurcumin therapy could regulate the Treg cells, and so could be useful in the treatment of AS and may be other autoimmune diseases. This study is registered with IRCT.ir, number IRCT2017052927520N7. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text